Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia Key PointsQuestionWhat are the long-term responses with combined ibrutinib and venetoclax first-line therapy in patients with chronic lymphocytic leukemia? FindingsIn this phase 2 nonrandomized trial, 80 previously untreated patients with chronic lymphocytic leukemia received combined ibrutinib and venetoclax for 24 cycles; on an intent-to-treat analysis, bone marrow–undetectable measurable residual disease remission was achieved by 56% of the patients at 12 cycles and 66% of the patients at 24 cycles of combined treatment. Overall, 75% of the patients achieved bone marrow–undetectable measurable residual disease remission as best response, with 3-year progression-free survival noted in 93% of the patients. MeaningThe findings of this study suggest that combination therapy with ibrutinib and venetoclax may be a useful regimen for previously untreated patients with chronic lymphocytic leukemia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/ibrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-zcCqORQlwS
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2021.1649
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat are the long-term responses with combined ibrutinib and venetoclax first-line therapy in patients with chronic lymphocytic leukemia? FindingsIn this phase 2 nonrandomized trial, 80 previously untreated patients with chronic lymphocytic leukemia received combined ibrutinib and venetoclax for 24 cycles; on an intent-to-treat analysis, bone marrow–undetectable measurable residual disease remission was achieved by 56% of the patients at 12 cycles and 66% of the patients at 24 cycles of combined treatment. Overall, 75% of the patients achieved bone marrow–undetectable measurable residual disease remission as best response, with 3-year progression-free survival noted in 93% of the patients. MeaningThe findings of this study suggest that combination therapy with ibrutinib and venetoclax may be a useful regimen for previously untreated patients with chronic lymphocytic leukemia.

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 10, 2021

References